Literature DB >> 25075752

Switch strategies in antiretroviral therapy regimens.

Eva Van den Eynde1, Daniel Podzamczer.   

Abstract

Despite great advances in antiretroviral therapy in the last decade, several limitations still remain such as adverse effects, lack of adherence and drug-drug interactions. Switching antiretroviral therapy in stable, virologically suppressed patients with the aim of improving tolerability and convenience is an expanding strategy in clinical practice. Several factors need to be taken into consideration when switching a suppressive regimen, such as previous virologic failure, genetic barrier of the new regimen, prior duration of virologic suppression and expected level of adherence. The most frequently used strategies include reductions in the number of pills, drugs or doses. Although switching strategies may be useful, not all the regimens used in clinical practice are based on data from randomized clinical trials and some may not be the best option for certain patients; therefore, therapy should be individualized taking into consideration available information as well as patient and drug characteristics.

Entities:  

Keywords:  HIV; antiretroviral therapy; monotherapy; simplification; switch

Mesh:

Substances:

Year:  2014        PMID: 25075752     DOI: 10.1586/14787210.2014.944506

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  7 in total

1.  Efficacy and safety of switching to abacavir/lamivudine (ABC/3TC) plus rilpivirine (RPV) in virologically suppressed HIV-infected patients on HAART.

Authors:  R Palacios; I A Pérez-Hernández; M A Martínez; M L Mayorga; C M González-Domenech; M Omar; J Olalla; A Romero; J M Romero; I Pérez-Camacho; J Hernández-Quero; J Santos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-02-15       Impact factor: 3.267

2.  Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfected patients.

Authors:  David Chromy; Philipp Schwabl; Theresa Bucsics; Bernhard Scheiner; Robert Strassl; Florian Mayer; Maximilian C Aichelburg; Katharina Grabmeier-Pfistershammer; Michael Trauner; Markus Peck-Radosavljevic; Thomas Reiberger; Mattias Mandorfer
Journal:  Wien Klin Wochenschr       Date:  2017-07-25       Impact factor: 1.704

3.  Safety and Efficacy of Dolutegravir Plus Rilpivirine in Treatment-Experienced HIV-Infected Patients: The DORIVIR Study.

Authors:  Rosario Palacios; M Mayorga; C M González-Domenech; C Hidalgo-Tenorio; C Gálvez; L Muñoz-Medina; J de la Torre; A Lozano; M Castaño; M Omar; Jesús Santos
Journal:  J Int Assoc Provid AIDS Care       Date:  2018 Jan-Dec

4.  Optimizing Antiretroviral Therapy in Treatment-Experienced Patients Living with HIV: A Critical Review of Switch and Simplification Strategies. An Opinion of the HIV Practice and Research Network of the American College of Clinical Pharmacy.

Authors:  Daniel Chastain; Melissa Badowski; Emily Huesgen; Neha Sheth Pandit; Andrea Pallotta; Sarah Michienzi
Journal:  J Int Assoc Provid AIDS Care       Date:  2019 Jan-Dec

5.  Cost-savings and potential cost-savings through the distribution of generic antiretroviral drugs within the statutory health insurance market of Germany between January 2017 and June 2019.

Authors:  Matthäus Lottes; Viviane Bremer; Christof Prugger; Christian Kollan; Daniel Schmidt
Journal:  BMC Health Serv Res       Date:  2022-01-13       Impact factor: 2.655

Review 6.  Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients.

Authors:  Sean E Collins; Philip M Grant; Robert W Shafer
Journal:  Drugs       Date:  2016-01       Impact factor: 9.546

7.  The treatment outcomes of antiretroviral substitutions in routine clinical settings in Asia; data from the TREAT Asia HIV Observational Database (TAHOD).

Authors:  In Young Jung; David Boettiger; Wing Wai Wong; Man Po Lee; Sasisopin Kiertiburanakul; Romanee Chaiwarith; Anchalee Avihingsanon; Junko Tanuma; Nagalingeswaran Kumarasamy; Adeeba Kamarulzaman; Fujie Zhang; Pacharee Kantipong; Oon Tek Ng; Benedict Lim Heng Sim; Matthew Law; Jeremy Ross; Jun Yong Choi
Journal:  J Int AIDS Soc       Date:  2017-12       Impact factor: 5.396

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.